Good Morning roaches! I hope everyone is wide awake this morning for a new alert. Take a look at NVLX (Nuvilex Inc.).
“Nuvilex is a cutting edge, innovative Company whose aim is to initiate a paradigm shift, generating revenue at the same time as creating cancer and other cell related solutions to treat important human diseases, such as pancreatic cancer while retaining our connections to natural products.”
Over the month of May, NVLX has been testing their therapeutic treatment of pancreatic cancer and is in process of FDA approval trials. After receiving favorable Phase I testing in early May and the big news that the Phase II trials were very successful, NVLX is moving rapidly through the trials. Here are the results from the Phase II clinical trial that was conducted:
— Results demonstrated a 100% increase in patients’ median survival rate
— The 1-year survival rate was twice that observed with the current gold standard
— Chemotherapy dose needed was only one-third the normal amount
— Improved quality of life was noted in more than half of the patients
These results are simply astonishing and the effects are inconceivable if the outcome is the same for the Phase IIb and III trials. With the company aggressively pursuing these trials in hopes that the results are just as positive, more press releases detailing the outcomes could be incoming.
NVLX is currently in a stage of consolidation with support appearing to lie around .06 and finally at .056. Temporary resistance falls in the mid 70s with the previous high at .104.
Keep an eye out for this one, roaches, and look for that bottom!
Disclosure: This corporate profile is provided for information purposes only and should not be used as the basis for any investment decision. We are neither licensed nor qualified to provide investment advice. We were not paid, nor do we hold a position in this stock. We reserve the right to buy or sell NVLX at any time after this post.